May 11, 2015
Interviewed by: David Snow
Video Clip
Login to view full video

Seeing Value in Infection Prevention

Baird Capital acquired Zurex, a company that makes products aimed at preventing hospital-acquired infections. The firm’s Mike Liang discusses why this was an appealing area to invest in.

Baird Capital acquired Zurex, a company that makes products aimed at preventing hospital-acquired infections. The firm’s Mike Liang discusses why this was an appealing area to invest in.

Seeing Value in Infection Prevention
With Mike Liang of Baird Capital

Why did Baird invest in a company making products to prevent hospital-acquired infections?

Mike Liang, Baird Capital: We looked at this whole space in a similar way. Thought it was an interesting area in terms of just where providers weren’t getting paid for people that had been diagnosed with hospital-acquired infections and had to treat them out of their own costs. So it’s going to be a big concern, and we started looking at the numbers and Mike mentioned some of them already, but one out of every 20 patients gets some type of hospital-acquired infection. I think the estimates are somewhere around North of $30 billion at a time when everyone’s trying to figure out how to safe costs. It seems like a natural, interesting area for investment. So as we started looking into this area, we actually have an investment in this space, a very interesting medical products company called Zurex based out of Madison, Wisconsin. We had tracked this company for a couple of years. The reason we liked this product was it was just a very interesting platform of anti-microbial solutions that could be used in, for different applications.

One of their lead programs is skin prep for surgical-site infections, very large market there and obviously used for every type of operating procedure. And they also had a very interesting solution, with good clinical data already, as a catheter-lock solution. So any time someone’s got a catheter and people need to put solutions in and out at the end of it, you have to try to clean it to a) keep the catheter open but also keep it from being infected. And right now today what people use is either normal saline, or sometimes they use heparin, which is good as an anti-coagulant but does nothing from the anti-infective properties. So what we saw here is an interesting company with a great platform of products that we could develop in an area that we were already very interested in and that, so far so good. That company is going quite well. But that’s an interesting example of what we love to be doing more of.

Register now to watch this video and access all content.

It's FREE!

  • CHOOSE YOUR NEWSLETTERS:
  • I agree to the Privcap terms of use and privacy policy
  • Already a subscriber? Sign In

  • This field is for validation purposes and should be left unchanged.